Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 245-250

  Kikuchi, Tetsuro ^a   Joki, Tatsuhiro ^a   Abe, Toshiaki ^a   Ohno, Tsuneya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Glioma; Interleukin 12; Interleukin 2; Lymphokineactivated killer cells

Indexed keywords

INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; HUMAN; IMMUNOPHARMACOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; MICE; RECOMBINANT PROTEINS; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0032911435     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00007     Document Type: Article

References (26)

1. Brandes A, Soesan M, Fiorentino M. Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res 1991; 11; 1988-92.
2. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70;175-82.
3. Kikuehi T, Nakamura N, Abe T, et al. Adoptive immunotherapy of brain tumors. Jikeikai Med J 1994;41;315-21.
4. Shimizu K, Okamoto Y, Miyao Y, et al. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 1987;66:519-21.
5. Yoshida S, Tanaka R, Takai N, et al. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988;48:5011-6.
6. Gately MK, Wolitzky AG, Quinn PM, et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992;143;127-42.
7. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7- induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992;148:2429-36.
8. Robertson Ml, Soiffer Rl, Wolf SF, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992;175:779-88.
9. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
10. Perussia B, Chan SH, D’Andrea A, et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 1992;149:3495-502.
11. Voest EE, Kenyon BM, O’Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
12. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994;6:157-67.
13. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-706.
14. Brunda MJ, Luistro L, Rumennik L, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 1996;38:16-21.
15. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996;17:214-7.
16. Zeh H 3, Hurd S, Storkus WI, et al. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother 1993;14:155-61.
17. Sakamoto K, Hoshino H, Kiuchi Y, et al. Potential usefulness of a cultured glioma cell line induced by rous sarcoma virus in BIO. A mouse as an immunotherapy model. Jpn J Exp Med 1989;59:173-80.
18. Kikuehi T, Watanabe M, Ohno T. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody. Jpn J Cancer Res 1991;82:339-45.
19. Daftarian PM, Kumar A, Kryworuchko M, et al. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol 1996;157:12-20.
20. Meyaard L, Hovenkamp E, Otto SA, et al. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol 1996;156:2776-82.
21. Windhagen A, Anderson DE, Carrizosa A, et al. IL-12 induces human T cells secreting IL-10 with IFN-gamma. J Immunol 1996;157:1127-31.
22. Leannin P, Delneste Y, Seveso M, et al. IL-12 synergizes with IL-2 and other stimuli in inducing IL-10 production by human T cells. J Immunol 1996;156:3159-65.
23. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991;174:1549-55.
24. MacNeil IA, Suda T, Moore KW, et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990;145:4167-73.
25. Schwarz MA, Hamilton LD, Tardelli L, et al. Stimulation of cytolytic activity by interleukin-10. J Immunother Emphasis Tumor Immunol 1994;16:95-104.
26. Rodolfo M, Zilocchi C, Melani C, et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 1996;157:5536-42.